Major Settlement Announced for QVAR and QVAR RediHaler Inhalers; Claim Your Share Today
In a significant development, Berman Tabacco, Sperling Kenny Nachwalter, LLC, and Hilliard Shadowen LLP have announced a class action settlement involving QVAR® and QVAR RediHaler® inhalers. This settlement follows allegations against Teva Pharmaceutical Industries Ltd. and its associates, who allegedly blocked generic versions of these inhalers from reaching the market, resulting in higher costs to consumers and third-party payors.
If you purchased, paid for, or provided reimbursement for QVAR® or QVAR RediHaler® inhalers between January 1, 2015, and July 31, 2025, you might be part of the affected group. This includes individuals or entities in various states, including California, Florida, New York, and many others, who acquired these inhalers for personal consumption rather than for resale.
Teva has agreed to contribute $35 million into a settlement fund designed to benefit eligible class members. This fund will cover several expenses, such as payments to class members, administration costs of the settlement, and attorney fees. Moreover, as part of the agreement, Teva will also list certain patents as delisted from the FDA's Orange Book, potentially paving the way for generic alternatives in the future.
To receive a payout from this settlement, affected individuals must complete a valid claim form. The final payment will depend on how many people file claims and the total number of inhalers purchased. More instructions and claim forms can be found at www.QVARAntitrustSettlement.com. Claims must be submitted by July 31, 2026.
It’s important for those affected to understand their rights in this situation. If you prefer to keep the right to pursue an individual lawsuit against Teva, you should exclude yourself from the settlement by June 15, 2026. Alternatively, individuals can object to the settlement by the same date. Full details are available on the class action website.
A court is scheduled to hold a hearing on August 5, 2026, to discuss the approval of the settlement, the methodology for distributing funds, and requests for attorney fees and other expenses. All affected individuals have the option to attend and express their opinions at the hearing, although they must do so at their own cost.
This settlement provides an opportunity for consumers who may have overpaid for necessary medication due to potential market manipulation. If you believe you are eligible for a claim, ensure you follow the necessary steps before the deadlines to secure your rights and compensation. For any inquiries, you can contact the claim center at 1-866-588-8524 or visit the aforementioned website for additional guidance.
Who is Affected?
If you purchased, paid for, or provided reimbursement for QVAR® or QVAR RediHaler® inhalers between January 1, 2015, and July 31, 2025, you might be part of the affected group. This includes individuals or entities in various states, including California, Florida, New York, and many others, who acquired these inhalers for personal consumption rather than for resale.
Settlement Details
Teva has agreed to contribute $35 million into a settlement fund designed to benefit eligible class members. This fund will cover several expenses, such as payments to class members, administration costs of the settlement, and attorney fees. Moreover, as part of the agreement, Teva will also list certain patents as delisted from the FDA's Orange Book, potentially paving the way for generic alternatives in the future.
Claim Process
To receive a payout from this settlement, affected individuals must complete a valid claim form. The final payment will depend on how many people file claims and the total number of inhalers purchased. More instructions and claim forms can be found at www.QVARAntitrustSettlement.com. Claims must be submitted by July 31, 2026.
Your Rights
It’s important for those affected to understand their rights in this situation. If you prefer to keep the right to pursue an individual lawsuit against Teva, you should exclude yourself from the settlement by June 15, 2026. Alternatively, individuals can object to the settlement by the same date. Full details are available on the class action website.
Upcoming Hearing
A court is scheduled to hold a hearing on August 5, 2026, to discuss the approval of the settlement, the methodology for distributing funds, and requests for attorney fees and other expenses. All affected individuals have the option to attend and express their opinions at the hearing, although they must do so at their own cost.
Conclusion
This settlement provides an opportunity for consumers who may have overpaid for necessary medication due to potential market manipulation. If you believe you are eligible for a claim, ensure you follow the necessary steps before the deadlines to secure your rights and compensation. For any inquiries, you can contact the claim center at 1-866-588-8524 or visit the aforementioned website for additional guidance.
Topics Other）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.